Adverse Event Management in HR+/HER2– Advanced Breast Cancer: PI3K/AKT/PTEN Pathway
Panelists discuss how targeted therapies and effective management of adverse events, particularly in relation to the PI3K/AKT/PTEN pathway, are crucial for optimizing treatment outcomes in hormone receptor (HR)–positive, HER2-negative advanced breast cancer.
EP. 1: Insights on Biomarker Testing in HR+/HER2- Advanced Breast Cancer
October 14th 2024Panelists discuss how biomarker testing plays a critical role in hormone receptor–positive, HER2-negative advanced breast cancer, emphasizing the timing of testing, the relevance of specific genomic assays, and the significant impact on prognosis and treatment decisions.
EP. 2: Role of PI3K/AKT/PTEN Pathway in HR+/HER2- Advanced Breast Cancer
October 21st 2024Panelists discuss how aberrations in the PI3K/AKT/PTEN pathway drive treatment resistance and disease progression following first-line therapy in hormone receptor–positive, HER2-negative advanced breast cancer, emphasizing the critical role of repeat biomarker testing to guide ongoing treatment strategies and enhance patient outcomes.
EP. 3: Overview of the CAPItello-291 Trial
October 21st 2024Panelists discuss the findings of the CAPItello-291 trial, which investigated capivasertib combined with fulvestrant in advanced hormone receptor–positive, HER2-negative breast cancer, leading to its approval in November 2023 and highlighting its potential as a new targeted therapy option in the second-line setting due to the prevalence of PIK3CA, AKT1, and PTEN alterations.
